Pneumonia, Viral Clinical Trial
Official title:
Helmet CPAP for Infants and Pediatric Patients With Acute Respiratory Distress
NCT number | NCT04764929 |
Other study ID # | AAAT5640 |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | August 7, 2021 |
Est. completion date | September 2022 |
Verified date | March 2022 |
Source | Columbia University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This a research study to find out whether giving Continuous Positive Airway Pressure (CPAP) through a Helmet is the same or better than giving CPAP through a Facemask, Nasal Mask, or Nasal Prongs. CPAP can help kids with lung infections breathe easier. The machine delivers pressurized air, which may help people with lung infections breathe more easily. Doctors routinely use a Facemask, Nasal Mask or Nasal Prongs to give CPAP for kids with lung infections, but the researchers want to know whether using Helmet CPAP is the same or better.
Status | Recruiting |
Enrollment | 30 |
Est. completion date | September 2022 |
Est. primary completion date | July 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 1 Month to 5 Years |
Eligibility | Inclusion Criteria: - One month to 5 years of age (inclusive) admitted to the PICU with community acquired pneumonia or bronchiolitis, having been stable on nasal or facemask CPAP for at least four hours but less than 48 hours, and parental informed consent. Exclusion Criteria: - Age less than 1 month or greater than 5 years - Positive for COVID-19 - Need for invasive mechanical ventilation or higher levels of non-invasive ventilation such as bi-level positive airway pressure (BPAP) - Unresponsiveness (GCS 8 or less) - Hypotension as defined as a systolic blood pressure less than 5th percentile for age - Existing head or neck trauma, known or suspected air leak syndrome (pneumothorax, pneumomediastinum, subcutaneous emphysema), known or suspected increased intracranial pressure - Non-English speaking parent |
Country | Name | City | State |
---|---|---|---|
United States | Columbia University Medical Center | New York | New York |
Lead Sponsor | Collaborator |
---|---|
Patrick Wilson |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Tolerability of helmet CPAP | Percentage of patients that tolerate helmet CPAP for at least four hours. Tolerance is defined as the successful application and maintenance of helmet CPAP without any unplanned, prolonged (>5 minutes) removals or disruptions. | Four hours | |
Secondary | Respiratory rate | We will measure respiratory rate in breaths per minute every hour blood pressure every hour for four hours. | Four hours | |
Secondary | Heart rate | We will measure heart rate in beats per minute every hour | Four hours | |
Secondary | Oxygen saturation | We will measure pulse oxygen saturation as a percent every hour | Four hours | |
Secondary | Systolic blood pressure | We will measure systolic blood pressure in millimeters of mercury every hour | Four hours |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04517123 -
Prone Position and Respiratory Outcomes in Non-Intubated COVID-19 PatiEnts The "PRONE" Study
|
N/A | |
Completed |
NCT04435327 -
Lung Damage Caused by SARS-CoV-2 Pneumonia (COVID-19)
|
||
Completed |
NCT01271842 -
Long-term Outcome and Lung Capacity in Survivors of ARDS Due to Influenza A (H1N1) v2009 The RESPIFLU Study
|
N/A | |
Completed |
NCT04724538 -
Inhalation Low Dose Radionuclide Therapy in Treatment COVID-19
|
Phase 1/Phase 2 | |
Recruiting |
NCT04414293 -
Low Dose Pulmonary Irradiation in Patients With COVID-19 Infection of Bad Prognosis
|
N/A | |
Completed |
NCT04047719 -
Pneumonia in the ImmunoCompromised - Use of the Karius Test for the Detection of Undiagnosed Pathogens
|
||
Recruiting |
NCT04528888 -
Steroids and Unfractionated Heparin in Critically Ill Patients With Pneumonia From COVID-19 Infection
|
Phase 3 | |
Completed |
NCT04606407 -
Inhaled NO for the Treatment of Viral Pneumonia in Adults
|
N/A | |
Terminated |
NCT04619693 -
Biomarkers for Dexamethasone Response in Sars-Cov-2 / COVID-19 Pneumonia
|
||
Recruiting |
NCT05077917 -
Cromolyn Sodium for Treatment of COVID-19 Pneumonia
|
Phase 3 | |
Withdrawn |
NCT04381923 -
COVIDNOCHE Trial (HFNO Versus CPAP Helmet) in COVID-19 Pneumonia
|
N/A | |
Recruiting |
NCT05976581 -
Using Probability of Community-Acquired Pneumonia to Tailor Antimicrobials Among Inpatients
|
N/A | |
Active, not recruiting |
NCT04381364 -
Inhalation of Ciclesonide for Patients With COVID-19: A Randomised Open Treatment Study (HALT COVID-19)
|
Phase 2 | |
Completed |
NCT04422613 -
Characterization of Persistent Pulmonary Abnormalities Following COVID-19 Pneumonia
|
N/A | |
Completed |
NCT04479540 -
Assessment of the Risk of Pulmonary Embolism and Coagulation Profile in Patients With COVID-19 Lung Disease
|
N/A | |
Recruiting |
NCT04474340 -
COVID-19 Convalescent Plasma Treatment in SARS-CoV-2 Infected Patients
|
Phase 1 | |
Completed |
NCT04424836 -
HFNC Treatment in COVID-19 Pneumonia
|
||
Active, not recruiting |
NCT04365101 -
Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19
|
Phase 1/Phase 2 | |
Completed |
NCT04387799 -
Determinants of COVID-19 Pneumonia (MC-19)
|
||
Completed |
NCT04382547 -
Treatment of Covid-19 Associated Pneumonia With Allogenic Pooled Olfactory Mucosa-derived Mesenchymal Stem Cells
|
Phase 1/Phase 2 |